

eTable 2: Univariate and multivariate Cox regression analyses for overall and progression-free survival in all patients.

Parameter	Overall survival				Progression-free survival			
	Univariate Cox regression		Multivariate Cox regression		Univariate Cox regression		Multivariate Cox regression	
	HR [95% CI]	p value	HR [95% CI]	p value	HR [95% CI]	p value	HR [95% CI]	p value
Treatment	0.91 [0.87 – 0.95]	< 0.0001	0.91 [0.86 – 0.96]	0.0003	0.95 [0.91 – 0.99]	0.01	0.94 [0.89 – 0.99]	0.012
Age	0.89 [0.75 – 1.04]	0.15	0.89 [0.74 – 1.07]	0.22	0.97 [0.83 – 1.13]	0.68	0.95 [0.79 – 1.13]	0.54
Gender	0.86 [0.75 – 1.06]	0.21	0.98 [0.81 – 1.20]	0.86	0.86 [0.73 – 1.01]	0.07	0.90 [0.74 – 1.09]	0.27
# metastatic sites	1.28 [1.17 – 1.39]	< 0.0001	1.27 [1.15 – 1.41]	< 0.0001	1.18 [1.09 – 1.29]	0.0001	1.22 [1.11 – 1.35]	< 0.0001
Primary tumor side	0.65 [0.54 – 0.78]	< 0.0001	0.76 [0.61 – 0.93]	0.009	0.67 [0.56 – 0.81]	< 0.0001	0.67 [0.55 – 0.82]	< 0.0001
RAS mutation vs. wild-type	1.40 [1.18 – 1.66]	< 0.0001	1.26 [1.04 – 1.52]	0.012	1.22 [1.04 – 1.44]	0.015	1.15 [0.96 – 1.38]	0.14
BRAF mutation vs. wild-type	1.19 [0.88 – 1.61]	0.25	1.40 [1.01 – 1.94]	0.04	1.19 [0.89 – 1.59]	0.24	1.42 [1.04 – 1.93]	0.03
PIK3CA mutation vs. wild-type	1.01 [0.77 – 1.34]	0.94	1.03 [0.75 – 1.42]	0.84	1.13 [0.87 – 1.48]	0.36	1.10 [0.82 – 1.49]	0.52
ECOG performance index	1.54 [1.33 – 1.78]	< 0.0001	1.49 [1.27 – 1.41]	< 0.0001	1.10 [0.96 – 1.26]	0.17	0.98 [0.84 – 1.13]	0.74
Normalized AREG expression	0.42 [0.24 – 0.74]	0.002	0.46 [0.25 – 0.85]	0.01	0.40 [0.24 – 0.69]	0.001	0.40 [0.22 – 0.71]	0.002

Legend: ECOG = Eastern Cooperative Oncology Group; AREG = Amphiregulin; HR = hazard ratio; 95% CI = 95% confidence interval. P values < 0.05 were considered significant and are displayed **bold**.